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 Abstract 20 
Background.  Community-associated (CA) Clostridium difficile infection (CDI) is a major public health 21 
problem.  This study estimates the magnitude of the association between temporal and cumulative 22 
prescription of antimicrobials in primary care and CA-CDI. CA-CDI is defined as cases without prior 23 
hospitalisation in the previous 12 weeks who were either tested outside of hospital or tested within 2 24 
days of admission to hospital. 25 
Methods.  Three National patient level datasets –covering CDI cases, community prescriptions and 26 
hospitalisations were linked by the NHS Scotland unique patient identifier, the community health 27 
index, CHI.  All validated cases of CDI from August 2010 to July 2013 were extracted and up to six 28 
population-based controls were matched to each case from the CHI register for Scotland.  Statistical 29 
analysis used conditional logistic regression. 30 
Results.  1446 unique cases of CA-CDI were linked with 7964 age, sex and location matched controls.  31 
Cumulative exposure to any antimicrobial in the previous 6 months has a monotonic dose-response 32 
association with CA-CDI.  Individuals with excess of 28 defined daily doses (DDD) to any antimicrobial 33 
(19.9% of cases) had an odds ratio (OR)=4.4 (95% CI:3.4-5.6) compared to those unexposed. 34 
Individuals exposed to 29+ DDD of high risk antimicrobials (cephalosporins, clindamycin co-amoxiclav, 35 
or fluoroquinolones) had an OR=17.9 (95% CI:7.6-42.2). Elevated CA-CDI risk following high risk 36 
antimicrobial exposure was greatest in the first month (OR=12.5 (8.9-17.4)) but was still present 4-6 37 
months later (OR=2.6 (1.7-3.9)). Cases exposed to 29+DDD had prescription patterns more consistent 38 
with repeated therapeutic courses, using different antimicrobials, than long term prophylactic use.  39 
Conclusions.  This analysis demonstrated temporal and dose-response associations between CA-CDI 40 
risk and antimicrobials with an impact of exposure to high risk antimicrobials remaining 4-6 months 41 
later.  42 
 43 
  44 
 Introduction 45 
Clostridium difficile infection (CDI) is a major public health problem and a key focus for antimicrobial 46 
stewardship programs.  Quantification of the adverse effects of antimicrobial use at population level 47 
is essential to support appropriate antimicrobial stewardship policy.  Community-associated CDI (CA-48 
CDI) is an increasing public health threat1 studies indicating 37-79% cases having had antimicrobial 49 
exposure in the preceding 90 days.2-7 A meta-analysis8 derived pooled odds ratios from eight studies 50 
for the risk of CA-CDI associated with specific antimicrobial groups, but did not consider cumulative or 51 
temporal exposure effects.  Cumulative and temporal antimicrobial exposure have been examined in 52 
healthcare-associated CDI (HA-CDI)9-11 but for CA-CDI data are limited to considering cumulative effect 53 
in an elderly population12 and considering temporal effects for overall antimicrobial exposure only, 13 54 
with both studies limited to low CA-CDI numbers. 55 
The increasing availability of routinely captured electronic administrative health data, readily linkable 56 
through use of unique patient identifiers, affords the opportunity to examine complex patterns of 57 
drug use over time at population level.  This supports the derivation of more accurate estimates of 58 
risk informing clinicians and policy-makers to improve patient treatment and minimise harm at 59 
individual and population level.  The aim of our study was to use nationally collected routine 60 
healthcare data to estimate associations between CA-CDI and prior prescription of antimicrobials in 61 
primary care, considering exposure to (i) any antimicrobial and (ii) specific broad-spectrum 62 
antimicrobials. We examined the effects of any exposure and cumulative exposure, and the temporal 63 
relationship between timing of antimicrobial exposure and risk of CA-CDI. 64 
  65 
 Materials and methods 66 
Data sources 67 
Three National Health Service (NHS) patient level datasets - Electronic Communication of Surveillance 68 
in Scotland (ECOSS); Prescribing Information System (PIS) and General / Acute and Inpatient Day Case 69 
dataset (SMR01) - all indexed by the NHS Scotland unique patient identifier CHI (Community Health 70 
Index) are linked as part of the Infection Intelligence Platform (IIP),14 allowing generation of the study 71 
dataset. The CHI register for Scotland was used for control assignment. The NHS in Scotland has 72 
universal coverage so all data, including prescribing,15 are representative of the whole population.   73 
ECOSS records all positive Clostridium difficile tests from NHS laboratories in Scotland through 74 
mandatory reporting, with standardisation of sampling, testing and reporting across all clinical 75 
settings. All diarrhoeal samples are tested in a 2-step algorithm; firstly, identifying the presence of C. 76 
difficle using glutamate dehydrogenase screening and secondly, identifying the presence of toxin using 77 
ELISA/PCR. Health Protection Scotland (HPS) then validates with the NHS health boards which positive 78 
tests represent individual, clinically symptomatic CDI episodes (toxin positive and experienced 79 
diarrhoea not attributable to any other cause). PIS records all prescriptions dispensed and reimbursed 80 
within primary care in Scotland. SMR01 contains episode level data on all hospital inpatient and day 81 
case discharges from hospitals in Scotland).16  82 
Data linkage and control assignment 83 
All validated CDI cases with test date from August 2010 to July 2013 were extracted from ECOSS and 84 
linked to hospitalisation histories from SMR01. Community-associated cases were defined as those 85 
without prior hospitalisation in the previous 12 weeks and were either tested outside of hospital 86 
(community-onset (CO)) or tested within 48 hours (2 days) of admission to hospital (healthcare-onset 87 
(HO))17 .  88 
CA-CDI cases were assigned up to six community-based controls from the CHI register for Scotland, 89 
matched on age (within 5 years), gender and location (intermediate zone derived from the patient’s 90 
postcode). For the healthcare-onset community-associated cases (CA-HO) hospital-based controls 91 
were additionally assigned - up to 6 controls were selected from hospitalised individuals without CDI 92 
admitted to the same hospital within 7 days of the CDI case’s admission date and who were still in 93 
hospital on the case’s CDI test date. 94 
For all cases and controls, prescription records from August 2009 from PIS were linked allowing 95 
assignment of antimicrobial, proton pump inhibitor (PPI) and H2 antagonist exposure in the six months 96 
 prior to CDI test date, and construction of comorbidity measures. Antimicrobial exposure, for this 97 
study defined as any systemic antibacterial, was defined as any exposure (present/absent), temporal 98 
exposure (how long prior to the test date the antimicrobial was prescribed) and cumulative exposure 99 
(in WHO ATC defined daily doses (DDD)),18 cumulating potentially multiple prescriptions in the 100 
previous 6 months.    101 
The prescribing measures of comorbidity were counts of the total number of prescriptions and the 102 
total number of different prescribed drugs (based on approved name) in the previous year. In addition, 103 
five years of hospitalisation records were used to construct a Charlson Index of comorbidity for all 104 
cases and controls based on ICD10 diagnosis discharge codes.19 Individuals with no hospitalisations in 105 
the previous 5 years were assigned an “unknown” Charlson index to differentiate from individuals 106 
with a hospitalisation and no recorded comorbidities, who were assigned a score of 0. Scottish Index 107 
of Multiple Deprivation (SIMD) quintiles – a measure of socioeconomic status which incorporates 108 
different aspects of deprivation into a single index, care home residence (yes/no) and NHS health 109 
board from the CHI Register was assigned to all records. 110 
All linkage was via CHI and case/control assignment was performed by the electronic Data Research 111 
and Innovation Service at NSS Information Services Division. No patient identifiers were available to 112 
the study team and all data were accessed via the National safe haven.   113 
Ethics 114 
Ethical permission for this study was not required as it used only non-identifiable routine data.  115 
Approval for the study was granted by NHS National Services Scotland Privacy Advisory Committee, 116 
Study number XRB13122.  117 
Statistical analysis 118 
Associations between antimicrobial exposure and CDI were assessed using conditional logistic 119 
regression. The distribution of potential confounding variables – previous hospital admissions, 120 
prescription totals, comorbidity score, care home residency status, PPI/H2 exposure and SIMD – was 121 
investigated in the cases and controls and adjusted for in the analysis. Four antimicrobial exposure 122 
groupings were examined:  any antimicrobials, a predefined broad-spectrum, high risk “4C” group [12] 123 
- clindamycin, cephalosporins, fluoroquinolones (ciprofloxacin (which accounts for >90% of all 124 
fluoroquinolone prescriptions in Scotland), levofloxacin, moxifloxacin, norfloxacin, and ofloxacin) and 125 
co-amoxiclav, all “non-4C” antimicrobials, and finally, fluoroquinolones only (FQs).  Interaction tests 126 
were used to investigate if the effects of antimicrobial prescribing are the same in those prescribed a 127 
PPI. 128 
 Sensitivity analyses examined the effect of restricting the definition of CA-CDI to cases with no 129 
hospitalisation in the previous 6 and 12 months.  We also provided stratified results for healthcare-130 
onset cases matched to both population and hospital-based controls.  All analysis was conducted using 131 
R version 3.2.1.  132 
 Results 133 
Between 1st Aug 2010 and 31st July 2013 there were 6019 confirmed CDI episodes in Scotland and 134 
1612 (26.8%) were CA-CDI. Of these, 1557 were successfully assigned population-based controls 135 
(Figure 1).  For the patients with more than one CA-CDI episode, a single episode was randomly 136 
selected resulting in a sample of 1446 cases with 7964 matched controls.    137 
Cases were more likely to have been in hospital in the previous year (43.0% versus14.0%) and exposed 138 
to PPIs (41.8% versus 22.4%), and had more comorbidity by both prescribing measures and Charlson 139 
Index (Table 1). Crude odds of CA-CDI were higher with higher comorbidity scores (Charlson Index 4 140 
or more versus 0 OR=4.2 (95% CI: 2,5-7.0)), with any hospital admission in the previous year (OR=4.9 141 
(95% CI: 4.3-5.6)), and with PPI or H2 antagonist exposure (Table 2).  After adjustment, the scale of 142 
these effects diminished but previous hospital admission (OR=2.15 (95% CI: 1.8-2.6), higher Charlson 143 
Index, and H2 antagonist exposure remained significant but PPI exposure did not (Table 2).  144 
Among cases, 58.7% were exposed to any antimicrobial in the previous 6 months compared to 23.0% 145 
of controls.  After adjustment, the odds of CA-CDI after any antimicrobial exposure was 2.8 (95% 146 
CI:2.4-3.2) compared to no antimicrobial exposure (Figure 2, Table 2). Adjusted odds of CA-CDI were 147 
even higher for prior exposure to 4C (OR=6.1 (95% CI:4.8-7.7)) and fluoroquinolone (OR=5.4 (95% CI: 148 
3.8-7.8)) antimicrobials.  149 
PPI exposure was common (Table 1) and significantly modified the effect of antimicrobial exposure 150 
(interaction test p=0.0001). Of cases, 26.7% were exposed to neither, 31.5% to only antimicrobials 151 
(OR=3.4 (95% CI:2.8-4.1) for CA-CDI), 14.6% to only PPIs (OR=1.38 (95% CI:1.1-1.7)) and 27.3% to both 152 
(OR=2.7 (95% CI:2.1-3.4)).  231 (16%) CA-CDI cases had no antimicrobial, PPI or H2 antagonist 153 
exposure, Charlson Index 0 and no previous hospitalisations.   154 
Sensitivity analysis to extend the exclusion period for prior hospitalisation from 12 weeks to 6 months 155 
led to marginally higher associations but little further change when using a 12-month exclusion. All CIs 156 
overlapped with the baseline results (4C exclusion 6 months OR=7.4 (95% CI:5.6-9.7); 12-month 157 
exclusion OR=7.1 (95% CI:4.9–10.3)). Considering the subset of CA-CDI cases with healthcare-onset, 158 
similar effect sizes were found for this group when matched to population-based controls (Table 3).  159 
Matching to hospital-based controls reduced the associations found – any antimicrobial exposure had 160 
an odds of CDI of 1.5 (95% CI:1.2-2.0) compared to no exposure and 4C exposure gave an increased 161 
odds of 2.17 (95% CI:1.5-3.3). 162 
Cumulative antimicrobial exposure was high with 19.9% of cases having 29+ DDDs in 6 months.  163 
Compared to no exposure, up to 7 DDD of any antimicrobial gives odds of CA-CDI of 2.3 (95% CI:1.9-164 
 2.9) compared to 4.4 (95% CI: 3.4-5.6) for 29+ DDDs (Table 4).  4C exposure duration was typically 165 
short among controls but more variable among cases.  Among cases 3.3% had 29+ DDDs of 4C which 166 
has associated odds of CDI of 17.9 (95% CI:7.6-42.2) compared to 4.6 (95% CI:3.4-6.2) for 1-7 DDDs, 167 
with similar pattern for cumulative fluoroquinolone exposure (Table 4).  Increasing durations of non-168 
4C antimicrobials increased CA-CDI risk, with odds ratio for 29+ DDDs of 3.9 (95% CI:3.0-5.1), which is 169 
about half the odds ratio for 29+ DDD of 4C exposure, 6.4 (95% CI:4.6-8.9). 170 
Among the 287 cases with 29+DDD exposure the pattern of antimicrobial prescribing is complex and 171 
more consistent with repeated short treatment courses prescriptions than long term prophylaxis 172 
(Supplementary Figure S1, supplementary Table S1). The most commonly prescribed antimicrobials 173 
were amoxycillin, trimethoprim, flucloxacillin, co-amoxiclav, ciprofloxacin and nitrofurantoin, each of 174 
which are prescribed to at least 20% of the 287 patients (Supplementary Table S2). 175 
Time since most recent antimicrobial treatment had a significant impact on CDI risk (Table 5).  176 
Considering any antimicrobial, the effect was strongest in those exposed in the previous 4 weeks, 177 
OR=6.3 (95% CI: 5.2-7.7) compared to OR=2.2 (95% CI:1.8-2.7) exposure 2-3 months earlier.  By 4-6 178 
months the effect of any exposure was lost OR=1.1 (95% CI:0.9-1.4) with a similar pattern observed 179 
for non-4C antimicrobials.   4C exposure within the previous month increased the odds of CDI 12.5 180 
(95% CI:8.9-17.4) times decreasing to OR=5.1 (95% CI: 3.5-7.5) by 2-3 months post exposure. The 181 
effects for both 4C and FQs were still significant 4-6 months post exposure (4C OR=2.6 95% CI:1.7-3.9). 182 
  183 
 Discussion 184 
In this whole population study we linked validated CDI cases to administrative datasets to quantify the 185 
risk of CA-CDI associated with community antimicrobial exposure. Any antimicrobial exposure within 186 
the previous 6 months increased the risk with elevated risk remaining for up to three months. We 187 
found larger associations with high risk antimicrobials and found even higher effects of cumulative 188 
exposure among this group and effects persisting up to six months following exposure.  189 
Our study established that 58.7% of CA-CDI cases had been exposed to an antimicrobial in the 190 
preceding 6 months, not dissimilar to other studies.2-7 A recent meta-analysis, including studies with 191 
significant heterogeneity and covering an earlier time frame,8 reported a higher OR for exposure to 192 
any antimicrobial OR=7.3 (95% CI: 4.3-12.6) compared to OR=2.8 in our study. Antimicrobial 193 
prescribing has changed over time, particularly in Scotland, in response to high rates and outbreaks of 194 
CDI in 2007/8.20 The antimicrobial with the strongest association with CA-CDI in the meta-analysis, 8 195 
clindamycin, was used very rarely in our study population (2.1% (31/1446) of cases and 0.03% (2/7964) 196 
controls have exposure in previous 6 months), and reduced prescribing of the whole 4C group has 197 
been successfully targeted in Scotland.21  198 
Consistent with this, our estimates are also lower than those reported by Marwick et al. 12. This case-199 
control component of this study focused only on elderly individuals in a single region of Scotland (n=62 200 
cases, 620 controls). Restricting our analysis to the same age group and geography yields similar 201 
estimates, though the confidence intervals become wide due to the small sample size (Supplementary 202 
Table S3).   203 
Cumulative total exposure to any antimicrobial has been clearly demonstrated to increase HA-CDI 204 
risk9-11 but evidence in CA-CDI is sparse.  Marwick et al. 12 found a dose-response relationship with OR 205 
of CDI increasing from 2.9 (95% CI: 1.2–6.7) for 1-7 days exposure to 12.7 (95% CI: 5.2-31.3) for 29+ 206 
days exposure – a higher magnitude than our study. This may partly reflect our inclusion of the entire 207 
population rather than only the elderly, known to be at higher risk of CDI. It may also be attributable 208 
to our classification of cumulative exposure as DDDs rather than days of therapy derived from 209 
prescription directions. 210 
There is little published evidence, even for HA-CDI, of the incremental impact of cumulative exposure 211 
of different groups of antimicrobials. Marwick et al. 12 generated ORs for cumulative 4C antimicrobials 212 
but the small sample size prevented meaningful subgroup analysis. Our inclusion of the whole 213 
population with confirmed CA-CDI in Scotland over a 3-year period enabled sub-analysis by 214 
antimicrobial group.  We demonstrate clear increasing odds of CA-CDI with increasing cumulative 215 
 exposure to antimicrobials and particularly for the 4C antimicrobial subgroup. For fluoroquinolones, 216 
the dose-response relationship remained, but there was higher variability surrounding the estimates, 217 
due to reducing prescription numbers.  218 
We found a high proportion (29.9%) of CA-CDI cases had received 29+ DDDs of antimicrobial in the 6 219 
months prior to CDI.  This included prescribing consistent with planned long term use for urinary tract 220 
infection prophylaxis (nitrofurantion, trimethoprim) and skin conditions (flucloxacillin, doxycycline) as 221 
may be expected, but the majority of cases involved various antimicrobials including ciprofloxacin, co-222 
amoxiclav and amoxicillin and the number of prescriptions and DDD per prescription was more 223 
consistent with multiple short treatment courses.  This prescribing pattern was unexpected and 224 
represents potentially avoidable, high risk antimicrobial prescribing and an important message for 225 
primary care prescribers.  226 
The period of increased risk of CDI following antimicrobial use remains an important clinical question.  227 
Previous studies have mainly examined, and found an increased risk associated with CA-CDI, up to 3 228 
months after antimicrobial use. 3,13,22 This has been affirmed in our study and is also similar to the risk 229 
observed in HA-CDI studies.10,11 One study13 examined prior antimicrobial use up to 180 days and found 230 
the increased risk remained up to 150 days (OR=2.8 95% CI:1.3-6.0) then returned to baseline.  In our 231 
study the period of elevated risk for any antimicrobials remained up to 3 months but was lost by 4-6 232 
months although was still elevated for 4C and fluoroquinolone antimicrobials.   This differential 233 
temporal impact of antimicrobial groups up to 6 months is an important finding to support clinical 234 
decision support and antimicrobial stewardship initiatives.    235 
The unadjusted effect of PPI prescribing was similar to that reported by previous meta-analysis22, but 236 
the effect diminished with covariate adjustment. The meta-analysis22 estimated a pooled OR of 1.93 237 
for the association between PPI exposure and CDI, but only three of 29 included studies involved CA-238 
CDI, with effect sizes of OR=0.9,23 OR=2.924 and OR=3.52 with each having differing case and exposure 239 
definitions. Whilst the effect of PPI exposure was diminished with covariate adjustment, the effect of 240 
H2 antagonists remained significant (OR=1.4).  This may be due to residual confounding, potentially 241 
attributable to prescription of H2 antagonists in preference to PPIs in patients who are deemed to be 242 
at a higher risk of CDI. 243 
After covariate adjustment, in particular adjustment for comorbidities (Charlson score and overall 244 
prescription counts), and accounting for antimicrobial prescribing, the effect of care home residence 245 
on CA-CDI became insignificant.  This effect was lower than the study of Marwick et al.12 which found 246 
a significant adjusted association with care home residence (OR=4.1 95% CI: 1.7-9.6), however, this 247 
 study, did not adjust for Charlson score.  Replicating the inclusion criteria and adjusting factors as 248 
Marwick et al.,12 analysis of our data gave a non-significant adjusted OR for care home residence of 249 
OR=2.2 (95% CI: 0.8-5.7) but similar effect sizes for cumulative antimicrobial prescribing, PPI exposure 250 
and total prescriptions in the previous year. The studies took place at different periods, Marwick et 251 
al.12 from November 2008-October 2009 and our study from 2010-2013 suggesting a reduction in the 252 
residual care home effect in the latter period perhaps attributable to improved stewardship over this 253 
time period.20 254 
This study illustrated that a sizeable proportion (16%) of individuals had exposure to neither PPIs, H2 255 
antagonists, nor antimicrobials, had not been an inpatient in the previous year and had no 256 
comorbidities recorded, indicating a significant proportion of CA-CDI cases which have not been 257 
exposed to the classically understood risk factors. These individuals were a younger subset of the cases 258 
(median age 48) but have a considerably higher number of community prescriptions than their 259 
matched controls indicating comorbidities not serious enough to require hospitalisation hence not 260 
captured reflected in the routinely used Charlson score. 261 
We believe the data in our study to be robust and have high levels of completeness.  Reporting of CDI 262 
is mandatory and all cases used in our analysis are validated. SMR01 covers all residents in Scotland 263 
that receive care in hospital enabling robust classification of community-associated disease.  264 
Antimicrobial exposure is assessed via an individual’s prescriptions dispensed in the community, which 265 
can be robustly measured15 and during the study period CHI completeness of the prescription data 266 
was between 94% and 96%.   267 
The main data limitation, which impacts on our CA-HO sub-analysis, is the lack of routine patient-level 268 
information on hospital prescribing, which is not presently captured electronically in Scotland.  The 269 
effect of this is mitigated to some extent because the CA-CDI definition excludes those with a 270 
hospitalisation in the previous 12 weeks, and our sensitivity analysis showed only marginal impact of 271 
extending the period for no prior hospitalisation to 12 months.  It does however hinder the 272 
generalizability this methodology to examine healthcare associated CDI. 273 
A further limitation, common to all observational studies of medication effects, is the inability to 274 
measure adherence and it is known that adherence to antimicrobials in the community is variable. 275 
Using dispensed prescribing data, as we have, is better in this regard than datasets based on 276 
prescriptions generated. 277 
Our findings have important implications for antimicrobial prescribing decisions in primary care, and 278 
for prescribing guidelines, emphasising that all exposure in the previous six months influences the risk 279 
 versus benefit of prescribing any antimicrobial, and specific antimicrobials. A significant number of 280 
patients in our study were at continually high CDI risk. The next phase of research should apply such 281 
routine data in cohort studies to derive clinical risk prediction scores and numbers needed to harm, 282 
to definitively quantify risk to help frontline clinicians to improve patient centred, safe and effective 283 
antimicrobial stewardship. 284 
In conclusion, this is the largest study to assess the impact of duration and time since antimicrobial 285 
therapy on CA-CDI and demonstrated that antimicrobial exposure had a clear dose response 286 
relationship, with the odds of CDI more than doubling when cumulative exposure was increased from 287 
one week to over 4 weeks.  The temporal effect of exposure is also clear. The risk is highest in the 288 
month after exposure but the effect of high risk broad-spectrum antimicrobials remains for up to six 289 
months. 290 
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 Table 1.  Distribution of matched and potential confounding variables in community-associated CA-364 
CDI CDI cases and population-based controls-presented as median and quartiles for the continuous 365 
variables and number and percentages for the categorical variables 366 
 Cases 
(n=1446) 
Matched Controls 
(n=7964) 
Age-median (IQRa) 71.5 (52-82) 69 (50-81) 
Female, n (%) 942 (65.2) 5186 (65.1) 
Male, n (%) 504 (34.8) 2778 (34.1) 
Number itemsb dispensed in previous year, 
median (IQR) 
59 (20-127.5) 17 (1- 47) 
Number different items dispensed in previous 
year (IQR) 
12 (7-18) 5(1-10) 
SIMDc 1: most deprived, n (%) 320 (22.2) 1580 (19.9) 
SIMD 2 323 (22.4) 1763 (22.2) 
SIMD 3 285 (19.8) 1641 (20.7) 
SIMD 4 261 (18.1) 1564 (19.7) 
SIMD 5: least deprived 252 (17.5) 1398 (17.6) 
Charlson scored 0, n (%) 705 (48.8) 3019 (37.9) 
Charlson score 1 167 (11.6) 260 (3.3) 
Charlson score 2 120 (8.3) 184 (2.3) 
Charlson score 3 41 (2.8) 55 (0.7) 
Charlson score 4+ 29 (2.0) 38 (0.5) 
Charlson score Unknown 384 (26.6) 4408 (55.4) 
Any hospital admission in previous year, n (%) 622 (43.0) 1118 (14.0) 
No hospital admission in previous year 824 (57.0) 6846 (96.0) 
Care home residence, n (%) 247 (17.1) 723 (9.1) 
No care home residence 1199 (82.9) 7241 (90.9) 
PPI exposure, n (%) 605 (41.8) 1785 (22.4) 
No PPI exposure 841 (58.2) 6179 (87.6) 
H2 exposure, n (%) 93 (6.4) 241 (3.0) 
No H2 exposure 1356 (94.6) 7723 (97.0) 
 367 
a Q1 is the lower quartile 1/4 of distribution below this point.  Q3 is the upper quartile 3/4 of the data below this point.  Q1 368 
to Q3 is known as the interquartile range IQR.  369 
b An item refers to any prescribed drug (based on approved name).  This total count is used as a measure of comorbidity. 370 
c SIMD is the Scottish Index of Multiple Deprivation here represented as quintiles 1-5. SIMD was unknown if this could not 371 
be linked from the CHI register-with 5 cases and 18 controls excluded for this reason. 372 
d High scores represent more comorbidity.  Unknown scores are generated if the individual has no previous hospitalisations 373 
in previous 5 years.   374 
 375 
  376 
 Table 2.  Unadjusted and adjusted odds ratios of CA-CDI together with 95% confidence intervals 377 
and p values from the fully adjusted model 378 
 Unadjusted Adjusted 
 OR (95% CI) OR (95% CI) p-value 
Exposed to antibiotics in the 
previous 6 months, No 
1 1 - 
Exposed to antibiotics in the 
previous 6 months, Yes 
4.98 (4.40-5.63) 2.80 (2.41- 3.25) <0.0001 
SIMDa 1: most deprived 1 1 - 
SIMD 2 0.86(0.71-1.05) 0.85 (0.67-1.08) 0.178 
SIMD 3 0.79 (0.64-0.98) 0.88 (0.68-1.14) 0.329 
SIMD 4 0.75 (0.60-0.94) 0.95 (0.72-1.24) 0.696 
SIMD 5: least deprived 0.83 (0.65-1.06) 0.98 (0.73-1.31) 0.872 
Charlson score 0 1 1 - 
Charlson score 1 3.59 (2.84- 4.53) 2.42 (1.82-3.21) <0.0001 
Charlson score 2 3.52 (2.71-4.57) 2.60 (1.89-3.57) <0.0001 
Charlson score 3 4.32 (2.81-6.62) 2.23 (1.33-3.74) 0.002 
Charlson score 4+ 4.19 (2.50-7.03) 2.83 (1.48-5.44) 0.002 
Charlson score Unknown 0.32 (0.28-0.37) 0.80 (0.67-0.96) 0.016 
Any hospital admission in previous 
year, No 
1 1 - 
Any hospital admission in previous 
year, Yes 
4.89 (4.30-5.57) 2.15 (1.80-2.56) <0.0001 
Number items dispensed in 
previous year 
1.019 (1.018-1.021) 1.011 (1.010-1.013) <0.0001 
Number different items dispensed 
in previous year 
1.16 (1.15-1.17) 1.03 (1.01-1.04) 0.002 
Care home residence, No 1 1 - 
Care home residence, Yes 2.54 (2.09-3.08) 1.15 (0.89-1.48) 0.283 
PPI exposure, No 1 1 - 
PPI exposure, Yes 2.62 (2.32-2.97) 1.02 (0.86-1.21) 0.819 
H2 antagonist exposure, No 1 1 - 
H2 antagonist exposure, Yes 2.21 (1.72-2.83) 1.41 (1.02-1.96) 0.036 
 379 
a SIMD is the Scottish Index of Multiple Deprivation here represented as quintiles 1-5.  380 
 381 
  382 
 Table 3.  Odds of CDI, together with 95% confidence intervals, given antibiotic exposure for 383 
community-associated healthcare-onset cases CA-HO matched to both population-based and 384 
hospital-based controls 385 
Exposure CA-HO n=476a  
matched to population-
based controls n=2581 
CA-HO n=476 a 
matched to hospital-based 
controls n=957 
 Adjusted OR (95% CI) Adjusted OR (95% CI) 
Any antibiotic exposure: Yes versus 
No 
2.21 (1.67-2.92) 1.52 (1.15-2.01) 
4C versus No antibiotic 4.91 (3.18-7.59) 2.17 (1.45-3.26) 
any other antibiotic versus No 
antibiotic 
1.66 (1.22-2.26) 1.32 (0.98-1.79) 
Fluoroquinolone versus No 
antibiotic 
5.22 (2.76-9.88) 2.14 (1.19-3.83) 
any other antibiotic versus No 
antibiotic 
1.96 (1.46-2.63) 1.44 (1.08-1.93) 
 386 
a Number of healthcare-onset cases reduces to n=476 when considering the cases which have both population and hospital-387 
based controls assigned to them. 388 
  389 
 Table 4.  The effect of cumulative exposure in a six month period on the adjusted odds of CA-CDI.  390 
Models are adjusted for SIMD, Charlson score, any hospitalisation in the previous year y/n, total 391 
number of prescriptions in the previous year, total number of different prescriptions, care home 392 
residence, PPI and H2 exposure 393 
Cumulative antimicrobial 
exposure 
Cases n (%) Controls n (%) Adjusted OR 
(95% CI) 
no antimicrobials 597 (41.4) 6133 (77.0) 1 
1-7 DDDs 198 (13.7) 659 (8.3) 2.31 (1.88-2.85) 
8-14 DDDs 166 (11.5) 584 (7.3) 2.13 (1.69-2.68) 
15-28 DDDs 195 (13.5) 334 (4.2) 3.59 (2.81-4.60) 
29+ DDDs 287 (19.9) 252 (3.2) 4.36 (3.40-5.61) 
NAa 3 2  
Cumulative 4C antimicrobial 
exposure  
   
no antimicrobials 597 (41.3) 6133 (77.0) 1 
1-7 DDDs 114 (7.9) 184 (2.3) 4.60 (3.41-6.21) 
8-14 DDDs 85 (5.9) 70 (0.9) 7.58 (5.05-11.37) 
15-28 DDDs 66 (4.6) 34 (0.4) 7.23 (4.25-12.28) 
29+ DDDs 47 (3.3) 10 (0.1) 17.86 (7.56-42.17) 
Any other non 4C 
antimicrobials 
536 (37.1) 1533 (19.2) 2.19 (1.86-2.58) 
NAa 1 0  
Cumulative fluoroquinolone 
exposure  
   
no antimicrobials 597 (41.3) 6133 (77.0) 1 
1-7 DDDs 48 (3.3) 72 (0.9) 3.82 (2.41-6.05) 
8-14 DDDs 32 (2.2) 19 (0.2) 10.13 (5.03-20.42) 
15-28 DDDs 25 (1.7) 5 (0.1) 7.29 (2.29-23.20) 
29+ DDDs 15 (1.0) 4 (0.1) 9.17 (2.26-37.14) 
Any other non 
fluoroquinolone antimicrobials 
728 (50.4) 1731 (21.7) 2.63 (2.26-3.07) 
NAa 1 0  
Cumulative non 4C 
antimicrobial exposure  
   
no antimicrobials 597 (41.3) 6133 (77.0) 1 
1-7 DDDs 194 (13.4) 634 (8.0) 2.33 (1.88-2.88) 
8-14 DDDs 159 (11.0) 560 (7.0) 1.98 (1.56-2.51) 
15-28 DDDs 167 (11.6) 298 (3.7) 3.03 (2.33-3.95) 
29+ DDDs 225 (15.6) 222 (2.8) 3.87 (2.95-5.09) 
Only 4C antimicrobials 102 (7.1) 115 (1.4) 6.39 (4.57-8.93) 
NAa 2 2  
 394 
aTo calculate DDD exposure both quantity and a scaling factor representing the recommended daily dose are required.  For 395 
5 observations either or both of these were missing for the antimicrobial exposure variable.  1 was missing for the FQ and 396 
4C exposure.  These observations are excluded from the analysis. 397 
In the exposure categories for 4C antibiotics individuals may be exposed to non 4C antibiotics as well; in the exposure 398 
categories for non 4C antibiotics individuals may be exposed to 4C antibiotics as well; in the exposure categories for 399 
fluoroquinolone antibiotics individuals may be exposed to non-fluoroquinolone antibiotics as well 400 
  401 
 Table 5. Distribution of temporal exposure and adjusted odds ratios of CA-CDI 402 
Most recent exposure in previous 6 
months 
% exposed 
controls 
n=7964 
% exposed 
cases 
n=1446 
Adjusted OR 
(95% CI) 
Global P 
value 
Any antimicrobial no antibiotics 77.0 41.3 1  0.064a 
 <= 1 month 6.1 32.0 6.3 (5.16-7.69)   
 2-3 months 8.1 17.8 2.2 (1.78-2.72)   
 4-6 months 8.7 8.9 1.1 (0.86-1.42)   
4C no antibiotics 77.0 41.3 1  <0.0001  
 <= 1 month 1.0 10.9 12.45 (8.89-17.44)   
 2-3 months 1.2 6.4 5.12 (3.5-7.51)   
 4-6 months 1.5 4.4 2.59 (1.74-3.87)   
 other antibiotic 19.2 37.1 2.17 (1.84-2.56)  
Fluoroquinolones no antibiotics 77.0 41.3 1 <0.0001  
 <= 1 month 0.3 3.1 11.06 (5.85-20.9)   
 2-3 months 0.5 3.0 4.96 (2.79-8.82)   
 4-6 months 0.5 2.2 3.13 (1.68-5.83)   
 other antibiotic 21.7 50.3 2.62 (2.25-3.06)  
Non 4C no antibiotics 77.0 41.3 1 <0.0001 
 <= 1 month 5.4 24.9 5.36 (4.34-6.62)  
 2-3 months 7.8 17.2 2.26 (1.82-2.80)  
 4-6 months 8.4 9.5 1.17 (0.91-1.51)  
 Only 4C 1.4 7.1 6.33 (4.50-8.91)  
 403 
aLinear trend test, evaluating by including temporal exposure as an ordered factor in the conditional logistic regression model 404 
 405 
 406 
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 Figures 408 
Figure 1: Flow chart of the episode selection and control assignment.  CA – Community-associated; 409 
CO – Community-onset; HO – Healthcare-onset. 410 
aNumbers of CA-HO cases differ in each analysis as they are matched to different control populations and not all cases are 411 
successfully matched. 412 
 413 
 414 
  415 
 Figure 2: Adjusted odds of CA-CDI, and 95% confidence intervals, following antimicrobial exposure in 416 
the previous 6 months compared to no antimicrobial exposure. Vertical dashed line at OR =1 417 
 418 
